RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a 'Sector Perform' rating on Biomarin Pharmaceutical (BMRN) and maintained a price target of $100.
February 23, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains a 'Sector Perform' rating on Biomarin Pharmaceutical with a $100 price target.
The reiteration of the 'Sector Perform' rating and maintenance of the $100 price target by RBC Capital suggests a neutral outlook for BMRN's stock in the short term. The analyst's view indicates stability in the company's prospects, without significant positive or negative changes expected imminently.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90